New UCLA research on menopause and cognition — see what Dr. Voskuhl's team found.
SHORTAGE ALERT: Estradiol patches (Climara, Vivelle-Dot, Teva, Mylan) are on indefinite backorder through 2026. See your options →
Brain-First Menopause Care
Your Patch Is Unavailable.
Your Brain Can't Wait.
It's not just an inconvenience.
It's an opportunity to ask a bigger question.
The 2026 estradiol patch shortage affects every major brand. While you navigate alternatives, discover why thousands of women are choosing PearlPAK® — the first menopause treatment designed specifically to protect cognitive health.
Brain-First Menopause Care
Your Patch Is Unavailable.
Your Brain Can't Wait.
It's not just an inconvenience.
It's an opportunity to ask a bigger question.
The 2026 estradiol patch shortage affects every major brand. While you navigate alternatives, discover why thousands of women are choosing PearlPAK® — the first menopause treatment designed specifically to protect cognitive health.
40 yrs
European Safety Data
$54M
NIH Funded Research
$147/mo
Rx + Delivery Included
24/7
Concierge Support
40 yrs
European Safety Data
$54M
NIH Funded Research
$147/mo
Rx + Delivery Included
24/7
Concierge Support
The Estradiol Patch Shortage Explained
2026
Shortage expected to continue through end of year
If you've gone to refill your estradiol patch recently, you've likely been told it's unavailable. Across the US, pharmacies are reporting the same message: estradiol patches are on indefinite backorder. The shortage affects all major brands — Climara, Vivelle-Dot, and generics from Teva and Mylan — with no clear resolution timeline.
The crisis stems from supply chain disruptions at multiple production facilities, compounded by record demand for menopausal hormone therapy (MHT). The FDA's November 2025 removal of the black box warning on MHT products contributed to a significant increase in prescriptions at a time when manufacturing capacity was already strained.
"For many women, this shortage may be the moment they start asking a bigger question: Is my current hormone therapy actually addressing my most important symptoms?"
Not All Estrogens Work the Same Way
When considering your options, it's important to understand the difference between estrogen types. Estradiol (patch) and oral estriol target different receptors that live in different parts of the body.
Estrogen Receptor Alpha
Abundant in reproductive tissues and breast. Estradiol binds strongly here. ERα activation drives the proliferative breast tissue effects associated with increased cancer risk in the Women's Health Initiative studies.
Estrogen Receptor Beta
Enriched in the hippocampus and prefrontal cortex — the brain regions responsible for verbal memory, processing speed, and executive function. These are the same regions that show measurable atrophy on MRI in menopausal women with untreated cognitive symptoms.
ERβ is enriched in the hippocampus and prefrontal cortex — the regions most affected by menopause-related cognitive decline.
70%
of menopausal women experience brain fog
40+
years of oral estriol safety data in Europe
Why Oral Estriol Changes Everything
Most hormone therapies use estradiol. PearlPAK® uses systemic estriol.
| Feature | CleopatraRx PearlPAK® — Oral Estriol (E3) Brain-first Menopause Care | Standard HRT Standard MHT — Estradiol (E2) Conventional hormone therapy |
|---|---|---|
| Primary Receptor | ✓ERβ — brain & nervous system | ~Broad — ERα + ERβ |
| Breast Tissue Exposure | ✓Weak — ERβ selective | ~Strong — ERα mediated |
| Converts to Estrone | ✓No | ~Yes — higher clotting risk with oral; lower with transdermal |
| Brain Fog Relief | ✓Primary indication | ~Unclear secondary / variable |
| Vasomotor Relief (Hot Flashes, Night Sweats) | ✓Very Good | ~Excellent |
| US Availability | ✓Compounded — licensed pharmacy | ~FDA-approved (patches in shortage 2026) |
| Safety Data | ✓40+ years (Asia & Europe) | ~Decades of use |
Why Estriol Changes Everything
Most hormone therapies use estradiol. PearlPAK® uses systemic estriol.
CleopatraRx
PearlPAK® — Oral Estriol (E3)
Brain-first Menopause Care
| Feature | PearlPAK® |
|---|---|
| Primary Receptor | ✓ERβ — brain & nervous system |
| Breast Tissue Exposure | ✓Weak — ERβ selective |
| Converts to Estrone | ✓No |
| Brain Fog Relief | ✓Primary indication |
| Vasomotor Relief (Hot Flashes, Night Sweats) | ✓Very Good |
| US Availability | ✓Compounded — licensed pharmacy |
| Safety Data | ✓40+ years (Asia & Europe) |
Standard HRT
Standard MHT — Estradiol (E2)
Conventional hormone therapy
| Feature | Standard MHT |
|---|---|
| Primary Receptor | ~Broad — ERα + ERβ |
| Breast Tissue Exposure | ~Strong — ERα mediated |
| Converts to Estrone | ~Yes — higher clotting risk with oral; lower with transdermal |
| Brain Fog Relief | ~Unclear secondary / variable |
| Vasomotor Relief (Hot Flashes, Night Sweats) | ~Excellent |
| US Availability | ~FDA-approved (patches in shortage 2026) |
| Safety Data | ~Decades of use |
Real Results From Real Women
★★★★★
"Almost immediately I started sleeping better — the brain fog started lifting within four or five months."
Jennifer A.
Former News Anchor, Age 61
Performance · Mood
★★★★★
"I feel 15 years younger and my brain fog has lifted — I'm able to recall words that I used to have a hard time remembering."
Sharon K.
Fitness Instructor, Age 49
Verbal Memory · Processing Speed
Real Results From Real Women
★★★★★
"Almost immediately I started sleeping better — the brain fog started lifting within four or five months."
Jennifer A.
Former News Anchor, Age 61
Performance · Mood
★★★★★
"I feel 15 years younger and my brain fog has lifted — I'm able to recall words that I used to have a hard time remembering."
Sharon K.
Fitness Instructor, Age 49
Verbal Memory · Processing Speed
As Seen In
Introducing PearlPAK®
PearlPAK® is a compounded estriol and progesterone protocol developed from Dr. Rhonda Voskuhl's NIH-funded research at UCLA. It is designed for women in perimenopause or menopause whose primary concern is cognitive health — while also supporting sleep disruption, mood changes, and hot flashes.
Consider PearlPAK® if you:
Experience brain fog, word-finding difficulty, or slowed processing as your primary symptom
Have a family history of cognitive decline and want a neuroprotective approach
Are concerned about long-term estradiol use and want a different receptor and safety profile
Had your patch discontinued and want to use this moment to reassess your treatment goals
The Science Behind PearlPAK®
The clinical foundation comes from Dr. Voskuhl's published research in multiple sclerosis. Women with MS consistently experience fewer relapses during pregnancy, when estriol levels peak naturally — and worsen after delivery when estriol disappears.
In the Phase 2b MS trial published in Lancet Neurology (2016), women treated with estriol showed improved cognitive processing speed, reduced cerebral cortex atrophy on MRI, and reduced blood biomarkers of neurodegeneration compared to placebo.
Cost & Access
$147/mo
Prescription, compounding pharmacy, delivery, and 24/7 concierge care team — all included. Available in most US states.
"Women's cognitive struggles during menopause were too often dismissed or misunderstood. I dedicated my career to changing that narrative — and giving women's health the scientific rigor it deserves."
Rhonda Voskuhl, MD
Neurologist · UCLA Distinguished Professor · Pioneering Women's Brain Health
Your Sharpness Is Worth Protecting.
The Menopause Cognitive Health Assessment was built to detect the early stages of cognitive changes from menopause. It takes just two minutes — and it's the first step toward treatment that actually addresses your brain.
PearlPAK® is a prescription product. Results may vary. This is not medical advice.
Your primary physician can also prescribe PearlPAK® using the prescriber portal.